Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

MicroRNA data in human EGFR positive versus EGFR negative colorectal cancer tissues

ABSTRACT: microRNA data in human EGFR positive versus EGFR negative colorectal cancer tissues

PROVIDER: PRJNA473846 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

microRNA data in human EGFR positive versus EGFR negative colorectal cancer tissues

Project description:This study was to identify microRNAs responsible for colorectal cancer

2018-05-31 | GSE115133 | GEO

RNA-seq of genetically engineered mouse EGFR positive glioblastoma tumors with PDGFRA and GAL-1 positive and negative populations

Project description:RNA-seq of genetically engineered mouse EGFR positive glioblastoma tumors flow cytometry sorted into PDGFRA and GAL-1 positive and negative populations.

2022-04-06 | GSE195813 | GEO

EGFR Interactome; PTEN positive and negative 5 min

Project description:A mechanism of EGFR regulation through the importin family RanBP6

2017-10-19 | MSV000081631 | MassIVE

Targeted inhibition of human breast cancer cell lines selected as model systems of ERBB2-positive/EGFR high breast cancer

Project description:This SuperSeries is composed of the following subset Series: GSE36324: Targeted inhibition of human breast cancer cell lines selected as model systems of ERBB2-positive/EGFR high breast cancer [RPPA-HCC1954] GSE36325: Targeted inhibition of human breast cancer cell lines selected as model systems of ERBB2-positive/EGFR high breast cancer [RPPA-Longterm] GSE36326: Targeted inhibition of human breast cancer cell lines selected as model systems of ERBB2-positive/EGFR high breast cancer [RPPA-SKBR3] Refer to individual Series

2012-10-22 | E-GEOD-36327 | biostudies-arrayexpress

Targeted inhibition of human breast cancer cell lines selected as model systems of ERBB2-positive/EGFR high breast cancer [RPPA-SKBR3]

Project description:EGFR-inhibition is required for targeted therapies of ERBB2-positive/EGFR high breast cancer. Approximately 30% of human ERBB2-positive breast tumors also express EGFR.

2012-10-22 | GSE36326 | GEO

Targeted inhibition of human breast cancer cell lines selected as model systems of ERBB2-positive/EGFR high breast cancer [RPPA-Longterm]

Project description:EGFR-inhibition is required for targeted therapies of EGFR high/ERBB2 positive breast cancer. Approximately 30% of human ERBB2 positive breast tumors also express EGFR.

2012-10-22 | GSE36325 | GEO

Targeted inhibition of human breast cancer cell lines selected as model systems of ERBB2-positive/EGFR high breast cancer [RPPA-HCC1954]

Project description:EGFR-inhibition is required for targeted therapies of ERBB2-positive/EGFR high breast cancer. Approximately 30% of human ERBB2-positive breast tumors also express EGFR.

2012-10-22 | GSE36324 | GEO

Targeted inhibition of human breast cancer cell line selected as model system of ERBB2-positive/EGFR high breast cancer [RPPA-Shortterm-SKBR3]

Project description:EGFR-inhibition is required for targeted therapies of ERBB2-positive/EGFR high breast cancer. Approximately 30% of human ERBB2-positive breast tumors also express EGFR.

2014-08-13 | GSE50106 | GEO

Targeted inhibition of human breast cancer cell line selected as model system of ERBB2-positive/EGFR high breast cancer [RPPA-Shortterm-HCC1954]

Project description:EGFR-inhibition is required for targeted therapies of ERBB2-positive/EGFR high breast cancer. Approximately 30% of human ERBB2-positive breast tumors also express EGFR.

2014-08-13 | GSE50105 | GEO

Targeted inhibition of human breast cancer cell lines selected as model systems of ERBB2-positive/EGFR high breast cancer [RPPA-Longterm]

Project description:EGFR-inhibition is required for targeted therapies of EGFR high/ERBB2 positive breast cancer. Approximately 30% of human ERBB2 positive breast tumors also express EGFR. Three therapeutics were analyzed in five combinations plus control. Each experiment was performed in three biological replicates. This resulted in 180 samples. A dilution series of control lysated was included as control.

2012-10-22 | E-GEOD-36325 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data